SEC Form 4 · accession 0001144204-16-086171
CASI Pharmaceuticals, Inc. · CASI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rajesh C Shrotriya M.D.
Director
Period of report
Mar 2, 2016
Accepted (ET)
Mar 4, 2016 · 4:50 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000895051
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $0.88 | Mar 2, 2016 | A | 35,000 | A | — | Mar 2, 2026 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1Stock option award will vest ratably quarterly to the end of one year.